@article {KerstjensP758, author = {H. Kerstjens and O. Kornmann and G. Desl{\'e}e and D. Young and D. Lawrence and D. McBryan}, title = {Once-daily indacaterol 150{\textmu}g or 300{\textmu}g and other bronchodilators in COPD patients of GOLD 2011 groups A and B}, volume = {42}, number = {Suppl 57}, elocation-id = {P758}, year = {2013}, publisher = {European Respiratory Society}, abstract = {IntroductionIndacaterol (IND) is an inhaled, once-daily, 24 hr long-acting β2-agonist for the treatment of COPD. We report on the effectiveness of IND and other long-acting bronchodilators compared to placebo in patients of GOLD 2011 groups A and B.MethodsA post-hoc, subgroup pooled analysis of 6-month efficacy data from 3 randomized, placebo controlled studies (n=3862) was performed across GOLD groups A{\textendash}D categorized according to FEV1 \% predicted, mMRC dyspnea scale and exacerbation history in the 12 months prior to entry (yes/no). Once-daily IND 150{\textmu}g or 300{\textmu}g, open-label tiotropium (TIO) 18{\textmu}g; twice-daily salmeterol (SAL) 50{\textmu}g or formoterol (FOR) 12{\textmu}g were compared to placebo. Endpoints included trough FEV1, TDI, and SGRQ total score, all at Week 26, and mean rescue medication use over 26 weeks.ResultsIn GOLD groups A and B, IND 150{\textmu}g and 300{\textmu}g significantly improved FEV1, TDI, SGRQ total score and mean rescue medication use compared with placebo.View this table:Adjusted mean treatment difference vs placeboConclusionTreatment selection according to patient{\textquoteright}s symptoms as well as risk is an important consideration in the treatment of COPD as per GOLD. IND 150{\textmu}g and 300{\textmu}g effectively improved lung function, health status, and symptoms in GOLD 2011 group A and B patients.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/42/Suppl_57/P758}, eprint = {https://erj.ersjournals.com/content/42/Suppl_57/P758.full.pdf}, journal = {European Respiratory Journal} }